Lyell Immunopharma (NASDAQ:LYEL) Upgraded to “Hold” at Wall Street Zen

Wall Street Zen upgraded shares of Lyell Immunopharma (NASDAQ:LYEL) from a sell rating to a hold rating in a research note issued to investors on Saturday,Wall Street Zen reports.

A number of other equities analysts have also issued reports on LYEL. Needham & Company LLC reiterated a “buy” rating and issued a $44.00 target price on shares of Lyell Immunopharma in a research report on Friday, September 11th. Stifel Nicolaus started coverage on shares of Lyell Immunopharma in a research report on Thursday, August 6th. They set a “buy” rating and a $36.00 price target on the stock. Royal Bank Of Canada set a $34.00 price target on shares of Lyell Immunopharma in a research note on Friday, August 14th. Weiss Ratings reiterated a “sell (d-)” rating on shares of Lyell Immunopharma in a report on Friday, July 17th. Finally, HC Wainwright reiterated a “buy” rating on shares of Lyell Immunopharma in a research note on Friday, September 11th. One investment analyst has rated the stock with a Strong Buy rating, six have issued a Buy rating, one has given a Hold rating and one has given a Sell rating to the company’s stock. Based on data from MarketBeat.com, the stock presently has an average rating of “Moderate Buy” and an average price target of $40.86.

Lyell Immunopharma Stock Performance

Shares of LYEL stock opened at $9.85 on Friday. Lyell Immunopharma has a 1 year low of $9.81 and a 1 year high of $45.00. The stock has a fifty day moving average of $13.29 and a two-hundred day moving average of $16.40. The firm has a market capitalization of $241.32 million, a PE ratio of -0.77 and a beta of -0.04.

Lyell Immunopharma (NASDAQ:LYEL) last issued its quarterly earnings results on Thursday, August 6th. The company reported ($1.92) EPS for the quarter, beating analysts’ consensus estimates of ($1.94) by $0.02. Lyell Immunopharma had a negative return on equity of 91.62% and a negative net margin of 920,285.25%.The company had revenue of $0.00 million for the quarter, compared to analyst estimates of $0.00 million. Equities research analysts predict that Lyell Immunopharma will post -7.2 earnings per share for the current fiscal year.

Institutional Inflows and Outflows

Large investors have recently bought and sold shares of the company. MWG Caph Ltd bought a new stake in Lyell Immunopharma in the fourth quarter worth about $31,030,000. Opaleye Management Inc. lifted its holdings in Lyell Immunopharma by 334.9% in the 2nd quarter. Opaleye Management Inc. now owns 344,025 shares of the company’s stock valued at $4,834,000 after acquiring an additional 264,928 shares during the last quarter. venBio Partners LLC acquired a new stake in Lyell Immunopharma in the 2nd quarter valued at about $4,744,643. Renaissance Technologies LLC boosted its position in shares of Lyell Immunopharma by 194.8% during the 1st quarter. Renaissance Technologies LLC now owns 116,411 shares of the company’s stock valued at $2,335,000 after purchasing an additional 76,921 shares in the last quarter. Finally, Velan Capital Investment Management LP boosted its position in shares of Lyell Immunopharma by 2.9% during the 2nd quarter. Velan Capital Investment Management LP now owns 105,000 shares of the company’s stock valued at $1,475,000 after purchasing an additional 3,000 shares in the last quarter. Institutional investors own 66.05% of the company’s stock.

About Lyell Immunopharma

Lyell Immunopharma, Inc is a clinical-stage biotechnology company focused on developing T-cell therapies for patients with cancer. The company’s research is aimed at addressing challenges that can limit the effectiveness of cellular immunotherapies, including T-cell exhaustion, inadequate persistence and difficulty penetrating solid tumors.

Lyell uses its cellular reprogramming and genetic engineering technologies to develop therapeutic T cells, including chimeric antigen receptor (CAR) T-cell candidates.